Search

Fasinumab

[A241190] It has since been recognized for its role in nociceptive signaling transduction and has thus become an attractive target in the treatment of chronic pain conditions.

Ad5-nCoV

being developed by CanSino Biologics Inc., in partnership with the Beijing Institute of Biotechnology, who in March 2020 announced the approval of a phase I clinical trial (ChiCTR2000030906)[L12675] with an

AV-COVID-19

As of July 2020, the company is pursuing an adaptive Phase IB-II Randomized Clinical Trial (NCT04386252) to test the vaccine.

NV1020

NV1020, a genetically engineered herpes simplex virus, is a novel anticancer therapeutic.

NGX267

NGX267 is a muscarinic agonist. It is developed for the treatment of Alzheimer’s disease and has shown the potential to both reduce symptoms and slow disease progression.

N-Acetylglucosamine

The N-acetyl derivative of glucosamine.

Laromustine

VNP40101M is a novel alkylating agent that has been used in trials studying the treatment of Leukemia, Lymphoma, Lung Cancer, Small Intestine Cancer, and Myelodysplastic Syndromes, among others.

Acetylcysteine zidrimer

Enlicitide

[L63795] Enlicitide is indicated as an adjunct to diet and exercise to reduce LDL-C in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH), and was studied in

Pegpleranib